NTRA

Natera, Inc. NASDAQ

Healthcare ·Medical - Diagnostics & Research ·US · natera.com

$211.56

Mkt Cap $30.0B

52w Low $131.81 64.0% of range 52w High $256.36

50d MA $202.00 200d MA $196.79

P/E (TTM) -136.4x

EV/EBITDA -115.4x

P/B 16.6x

Debt/Equity 0.1x

ROE -12.2%

P/FCF 287.1x

RSI (14) —

ATR (14) —

Beta 1.68

50d MA $202.00

200d MA $196.79

Avg Volume 1.2M

About

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determ…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-0.51	0.35	+168.4%	216.10	-2.4%	-3.7%	-7.4%	-4.2%	-6.0%	-8.8%	—
Nov 6, 2025	AMC	-0.39	-0.64	-65.9%	198.48	-6.1%	+0.5%	+4.1%	+4.2%	+5.6%	+1.1%	—
Aug 7, 2025	AMC	-0.62	-0.74	-20.2%	141.08	+14.8%	+7.7%	+11.3%	+13.3%	+11.8%	+12.3%	—
May 8, 2025	AMC	-0.64	-0.50	+21.9%	162.57	+1.3%	-6.5%	-3.2%	-6.3%	-6.9%	-8.1%	—
Feb 27, 2025	AMC	-0.38	-0.41	-7.6%	156.61	+2.1%	-0.7%	-8.6%	-9.1%	-5.5%	-9.6%	—
Nov 12, 2024	AMC	-0.57	-0.26	+54.4%	135.12	+15.1%	+19.1%	+11.8%	+8.1%	+13.5%	+20.0%	—
Aug 8, 2024	AMC	-0.69	-0.30	+56.5%	107.70	-2.0%	+6.4%	+7.0%	+10.5%	+10.0%	+13.5%	—
May 9, 2024	AMC	-0.71	-0.56	+21.1%	95.55	+13.1%	+10.2%	+8.1%	+10.4%	+12.3%	+13.6%	—
Feb 28, 2024	AMC	-0.73	-0.64	+12.3%	76.55	+12.0%	+13.0%	+16.8%	+17.8%	+14.5%	+17.9%	—
Nov 8, 2023	AMC	-0.96	-0.95	+1.0%	41.34	+14.9%	+9.8%	+13.1%	+17.4%	+26.1%	+28.1%	—
Aug 3, 2023	AMC	-1.09	-0.97	+11.0%	43.40	+14.0%	+17.6%	+17.6%	+21.5%	+20.4%	+22.9%	—
May 9, 2023	AMC	-1.15	-1.23	-7.0%	53.00	+2.6%	-3.4%	-2.6%	-3.6%	-1.6%	-3.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 3	Morgan Stanley	Maintains	Overweight → Overweight	—	$200.17	$195.67	-2.2%	+3.4%	+1.4%	-1.5%	-1.0%	+2.5%
Feb 27	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$216.10	$211.02	-2.4%	-3.7%	-7.4%	-4.2%	-6.0%	-8.8%
Feb 27	Evercore ISI	Maintains	Outperform → Outperform	—	$216.10	$211.02	-2.4%	-3.7%	-7.4%	-4.2%	-6.0%	-8.8%
Feb 27	Baird	Maintains	Outperform → Outperform	—	$216.10	$211.02	-2.4%	-3.7%	-7.4%	-4.2%	-6.0%	-8.8%
Jan 5	Guggenheim	Maintains	Buy → Buy	—	$228.84	$229.88	+0.5%	+3.7%	+8.7%	+11.2%	+4.7%	+2.4%
Dec 22	Canaccord Genuity	Maintains	Buy → Buy	—	$231.96	$233.91	+0.8%	+1.6%	+1.5%	+1.5%	+0.8%	-0.3%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$231.95	$229.29	-1.1%	-1.5%	-2.0%	-2.8%	-3.1%	+0.0%
Dec 15	JP Morgan	Maintains	Overweight → Overweight	—	$231.95	$229.29	-1.1%	-1.5%	-2.0%	-2.8%	-3.1%	+0.0%
Dec 15	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$231.95	$229.29	-1.1%	-1.5%	-2.0%	-2.8%	-3.1%	+0.0%
Dec 8	Canaccord Genuity	Maintains	Buy → Buy	—	$244.55	$245.33	+0.3%	-2.2%	-3.7%	-4.7%	-5.5%	-5.2%
Dec 5	BTIG	Maintains	Buy → Buy	—	$242.06	$242.22	+0.1%	+1.0%	-1.2%	-2.7%	-3.7%	-4.5%
Dec 2	Morgan Stanley	Maintains	Overweight → Overweight	—	$234.25	$236.95	+1.2%	+1.0%	+1.7%	+3.3%	+4.4%	+2.1%
Nov 25	JP Morgan	Maintains	Overweight → Overweight	—	$238.58	$240.40	+0.8%	-0.9%	-0.6%	+0.1%	-1.8%	-0.8%
Nov 18	UBS	Maintains	Buy → Buy	—	$206.04	$204.73	-0.6%	+3.7%	+6.0%	+9.5%	+11.9%	+15.8%
Nov 13	Stephens & Co.	Maintains	Overweight → Overweight	—	$209.50	$206.46	-1.5%	-4.2%	-2.5%	-1.7%	+2.0%	+4.2%
Nov 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$206.63	$207.44	+0.4%	+0.0%	+1.4%	-2.9%	-1.1%	-0.3%
Nov 11	Piper Sandler	Maintains	Overweight → Overweight	—	$206.63	$207.44	+0.4%	+0.0%	+1.4%	-2.9%	-1.1%	-0.3%
Nov 7	Barclays	Maintains	Overweight → Overweight	—	$198.48	$186.28	-6.1%	+0.5%	+4.1%	+4.2%	+5.6%	+1.1%
Nov 7	JP Morgan	Maintains	Overweight → Overweight	—	$198.48	$186.28	-6.1%	+0.5%	+4.1%	+4.2%	+5.6%	+1.1%
Nov 7	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$198.48	$186.28	-6.1%	+0.5%	+4.1%	+4.2%	+5.6%	+1.1%
Nov 7	Evercore ISI	Maintains	Outperform → Outperform	—	$198.48	$186.28	-6.1%	+0.5%	+4.1%	+4.2%	+5.6%	+1.1%
Nov 7	BTIG	Maintains	Buy → Buy	—	$198.48	$186.28	-6.1%	+0.5%	+4.1%	+4.2%	+5.6%	+1.1%
Nov 7	Canaccord Genuity	Maintains	Buy → Buy	—	$198.48	$186.28	-6.1%	+0.5%	+4.1%	+4.2%	+5.6%	+1.1%
Oct 23	BTIG	Maintains	Buy → Buy	—	$188.02	$187.16	-0.5%	+3.7%	+2.4%	+2.2%	+0.8%	+2.5%
Oct 14	Canaccord Genuity	Maintains	Buy → Buy	—	$174.17	$173.00	-0.7%	-0.8%	+3.0%	+3.7%	+4.3%	+8.3%
Aug 15	Stephens & Co.	Maintains	Overweight → Overweight	—	$158.44	$158.46	+0.0%	+2.9%	+1.7%	+1.1%	+1.4%	+2.2%
Aug 11	Piper Sandler	Maintains	Overweight → Overweight	—	$151.95	$151.05	-0.6%	+3.3%	+5.2%	+3.8%	+4.3%	+7.3%
Aug 8	RBC Capital	Maintains	Outperform → Outperform	—	$141.08	$162.00	+14.8%	+7.7%	+11.3%	+13.3%	+11.8%	+12.3%
Aug 8	Barclays	Maintains	Overweight → Overweight	—	$141.08	$162.00	+14.8%	+7.7%	+11.3%	+13.3%	+11.8%	+12.3%
May 15	Piper Sandler	Maintains	Overweight → Overweight	—	$151.34	$151.34	+0.0%	-1.3%	+0.8%	+1.3%	+2.1%	-0.2%
May 9	UBS	Maintains	Buy → Buy	—	$162.57	$164.75	+1.3%	-6.5%	-3.2%	-6.3%	-6.9%	-8.1%
May 9	Barclays	Maintains	Overweight → Overweight	—	$162.57	$164.75	+1.3%	-6.5%	-3.2%	-6.3%	-6.9%	-8.1%
Apr 10	Barclays	Maintains	Overweight → Overweight	—	$151.97	$146.24	-3.8%	-5.7%	-2.6%	-2.3%	-0.2%	-1.2%
Mar 5	Morgan Stanley	Maintains	Overweight → Overweight	—	$142.35	$142.09	-0.2%	+3.9%	-0.6%	-1.2%	-6.8%	-1.6%
Mar 4	Piper Sandler	Maintains	Overweight → Overweight	—	$143.11	$140.37	-1.9%	-0.5%	+3.4%	-1.1%	-1.7%	-7.3%
Feb 28	Canaccord Genuity	Maintains	Buy → Buy	—	$156.61	$159.94	+2.1%	-0.7%	-8.6%	-9.1%	-5.5%	-9.6%
Feb 28	Baird	Maintains	Outperform → Outperform	—	$156.61	$159.94	+2.1%	-0.7%	-8.6%	-9.1%	-5.5%	-9.6%
Feb 26	Canaccord Genuity	Maintains	Buy → Buy	—	$156.00	$155.31	-0.4%	+2.9%	+0.4%	-0.3%	-8.3%	-8.8%
Jan 28	Goldman Sachs	Maintains	Buy → Buy	—	$165.26	$165.49	+0.1%	+1.7%	+1.8%	+6.7%	+7.1%	+6.8%
Jan 17	Guggenheim	Maintains	Buy → Buy	—	$168.50	$168.92	+0.2%	-6.0%	-0.6%	+2.0%	+2.0%	-0.5%
Jan 10	Bernstein	Maintains	Outperform → Outperform	—	$176.61	$173.02	-2.0%	-0.9%	-4.1%	-6.1%	-3.5%	-4.6%
Jan 3	Canaccord Genuity	Maintains	Buy → Buy	—	$160.60	$162.65	+1.3%	+4.4%	+7.3%	+6.1%	+10.0%	+9.0%
Dec 13	JP Morgan	Maintains	Overweight → Overweight	—	$166.45	$168.20	+1.1%	+0.1%	+2.6%	+1.1%	-6.8%	-5.0%
Nov 18	Piper Sandler	Maintains	Overweight → Overweight	—	$146.06	$150.60	+3.1%	+5.0%	+11.0%	+14.9%	+16.0%	+14.5%
Nov 14	Morgan Stanley	Maintains	Overweight → Overweight	—	$160.97	$160.79	-0.1%	-6.1%	-9.3%	-4.7%	+0.7%	+4.3%
Nov 13	Canaccord Genuity	Maintains	Buy → Buy	—	$135.12	$155.56	+15.1%	+19.1%	+11.8%	+8.1%	+13.5%	+20.0%
Nov 13	TD Cowen	Maintains	Buy → Buy	—	$135.12	$155.56	+15.1%	+19.1%	+11.8%	+8.1%	+13.5%	+20.0%
Nov 13	Baird	Maintains	Outperform → Outperform	—	$135.12	$155.56	+15.1%	+19.1%	+11.8%	+8.1%	+13.5%	+20.0%
Nov 13	JP Morgan	Maintains	Overweight → Overweight	—	$135.12	$155.56	+15.1%	+19.1%	+11.8%	+8.1%	+13.5%	+20.0%
Nov 13	Craig-Hallum	Maintains	Buy → Buy	—	$135.12	$155.56	+15.1%	+19.1%	+11.8%	+8.1%	+13.5%	+20.0%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

Natera's executive compensation structure includes multi-year equity vesting incentives through 2029, indicating management retention strategy but diluting shareholder value over time through substantial stock awards.

Apr 1

8-K

Natera, Inc. -- 8-K Filing

Natera reported fourth quarter and full year 2025 financial results, with CFO Michael Brophy executing the filing on February 26, 2026.

Feb 26

Data updated apr 26, 2026 4:01pm · Source: massive.com